Scantox Launches Cloud-Based Mutagenesis App for DuplexSeq™

Scantox Group has introduced the new Scantox DuplexSeq Mutagenesis App, hosted on an upgraded bioinformatics platform. This launch enhances access to DuplexSeq™ Mutagenesis Assays with improved reagent kits, available now, and a scalable bioinformatics pipeline expected to expand in Q3 2026.

The cloud-based platform, developed with the guidance of Clint Valentine, aims to position error-corrected sequencing at the core of genomic safety evaluations. Scantox's partnership with LatchBio offers improved data management and user experience suitable for regulated scientific environments. Testing against TwinStrand's validation dataset confirmed consistent outputs with the original pipeline.

In addition, users benefit from centralized data, enhanced visualization, and customized reporting. The platform will support seamless data uploads for existing users, ensuring compliance with industry standards like 21 CFR Part 11 and SOC 2 Type II.